[go: up one dir, main page]

AR083044A1 - Anticuerpos anti-cd48 y usos de los mismos - Google Patents

Anticuerpos anti-cd48 y usos de los mismos

Info

Publication number
AR083044A1
AR083044A1 ARP110103412A ARP110103412A AR083044A1 AR 083044 A1 AR083044 A1 AR 083044A1 AR P110103412 A ARP110103412 A AR P110103412A AR P110103412 A ARP110103412 A AR P110103412A AR 083044 A1 AR083044 A1 AR 083044A1
Authority
AR
Argentina
Prior art keywords
antibodies
bind
treatment
certain embodiments
same
Prior art date
Application number
ARP110103412A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45870888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083044(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR083044A1 publication Critical patent/AR083044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud proporciona anticuerpos que se unen a CD48 y métodos de uso de los mismos. De acuerdo con ciertas realizaciones, los anticuerpos son anticuerpos completamente humanos que se unen a CD48 humano. En ciertas realizaciones, los anticuerpos divulgados bloquean la unión de CD48 a uno o más receptores de CD48. Los anticuerpos son útiles, para el tratamiento de enfermedades y trastornos asociados a una o más actividades biológicas de CD48, que incluyen el tratamiento de afecciones alérgicas y otras afecciones inflamatorias.
ARP110103412A 2010-09-27 2011-09-19 Anticuerpos anti-cd48 y usos de los mismos AR083044A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38674610P 2010-09-27 2010-09-27
US201161475280P 2011-04-14 2011-04-14
US201161515490P 2011-08-05 2011-08-05

Publications (1)

Publication Number Publication Date
AR083044A1 true AR083044A1 (es) 2013-01-30

Family

ID=45870888

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103412A AR083044A1 (es) 2010-09-27 2011-09-19 Anticuerpos anti-cd48 y usos de los mismos

Country Status (19)

Country Link
US (1) US9228014B2 (es)
EP (1) EP2621952A1 (es)
JP (2) JP6096117B2 (es)
KR (1) KR20140014067A (es)
CN (1) CN103261226B (es)
AR (1) AR083044A1 (es)
AU (1) AU2011312623B2 (es)
BR (1) BR112013007314A2 (es)
CA (1) CA2812748A1 (es)
CL (1) CL2013000843A1 (es)
EA (1) EA030437B1 (es)
IL (1) IL225484A (es)
MX (1) MX348417B (es)
MY (1) MY165273A (es)
NZ (1) NZ608660A (es)
PH (1) PH12013500564A1 (es)
SG (1) SG189089A1 (es)
TW (1) TWI507416B (es)
WO (1) WO2012047567A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
AU2013282353B2 (en) * 2012-06-28 2018-10-25 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10435463B2 (en) * 2014-09-05 2019-10-08 Academisch Medisch Centrum Hepatitis C virus specific antibody
AU2016232839B2 (en) * 2015-03-18 2021-02-25 Seagen Inc. CD48 antibodies and conjugates thereof
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP6805884B2 (ja) 2017-02-28 2020-12-23 住友ゴム工業株式会社 二輪自動用空気入りタイヤ
KR102659791B1 (ko) 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
AU2018392334A1 (en) 2017-12-22 2020-05-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
JP7349998B2 (ja) 2018-01-31 2023-09-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
JP2021514609A (ja) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス混入物質を同定するためのシステムおよび方法
EP3768709B1 (en) 2018-03-19 2023-12-27 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MX2021002279A (es) 2018-08-27 2021-05-27 Regeneron Pharma Uso de espectroscopia raman en la purificacion corriente abajo.
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
FI3857237T3 (fi) 2019-01-16 2023-05-03 Regeneron Pharma Disulfidisidosten luonnehtimismenetelmiä
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
EP4034870A1 (en) 2019-09-24 2022-08-03 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
EP4065086A1 (en) 2019-11-25 2022-10-05 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
MX2022014974A (es) 2020-05-26 2023-01-11 Boehringer Ingelheim Int Anticuerpos anti-pd-1.
TW202225398A (zh) 2020-08-31 2022-07-01 美商再生元醫藥公司 用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略
AU2021388021A1 (en) * 2020-11-24 2023-06-22 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
CA3191141A1 (en) 2020-11-25 2022-06-02 Hunter Chen Sustained release formulations using non-aqueous membrane emulsification
US20220257707A1 (en) 2020-12-17 2022-08-18 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
MX2023010794A (es) 2021-03-26 2023-10-25 Regeneron Pharma Metodos y sistemas para el desarrollo de protocolos de mezcla.
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
US20230090912A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
MX2024004107A (es) 2021-10-07 2024-04-19 Regeneron Pharma Sistemas y metodos para modelar y controlar el ph.
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
AR128824A1 (es) 2022-03-18 2024-06-19 Regeneron Pharma Métodos de análisis y cuantificación de variantes polipeptídicas de carga
US20240198253A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
US20240255519A1 (en) 2023-02-01 2024-08-01 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
KR20240147948A (ko) * 2023-03-29 2024-10-10 웰마커바이오 주식회사 Igsf1 특이적 결합 단백질 및 이의 용도
WO2024229136A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692405A (en) 1985-03-05 1987-09-08 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to antigen on activated human B-cells and assay therefor, protein antigenic determinant therefor and method of making same
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
WO1997035614A1 (en) 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
WO2005094886A1 (ja) 2004-03-31 2005-10-13 Kirin Beer Kabushiki Kaisha Gpiアンカー蛋白質アゴニストによる調節性t細胞分化誘導・増殖方法およびそのための医薬組成物
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8409565B2 (en) * 2006-02-14 2013-04-02 Francesca Levi-Schaffer Therapeutic target and diagnostic marker for asthma and related conditions
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP2418222B1 (en) 2009-04-10 2016-11-02 Osaka University Therapeutic agent for treating diseases in which neoplastic proliferation of plasma cells occurs

Also Published As

Publication number Publication date
AU2011312623A1 (en) 2013-05-02
MX348417B (es) 2017-06-12
KR20140014067A (ko) 2014-02-05
CA2812748A1 (en) 2012-04-12
US20120076790A1 (en) 2012-03-29
JP2017036324A (ja) 2017-02-16
PH12013500564A1 (en) 2021-06-02
WO2012047567A1 (en) 2012-04-12
EA030437B1 (ru) 2018-08-31
US9228014B2 (en) 2016-01-05
CL2013000843A1 (es) 2014-03-07
IL225484A0 (en) 2013-06-27
CN103261226A (zh) 2013-08-21
JP6096117B2 (ja) 2017-03-15
BR112013007314A2 (pt) 2017-03-21
JP2013542194A (ja) 2013-11-21
TW201305206A (zh) 2013-02-01
EP2621952A1 (en) 2013-08-07
NZ608660A (en) 2015-03-27
AU2011312623B2 (en) 2016-12-15
IL225484A (en) 2017-07-31
TWI507416B (zh) 2015-11-11
EA201370081A1 (ru) 2013-12-30
MX2013003468A (es) 2013-05-31
MY165273A (en) 2018-03-20
SG189089A1 (en) 2013-05-31
CN103261226B (zh) 2016-06-15

Similar Documents

Publication Publication Date Title
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
NI201200014A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana
UY34988A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso
CO2017002719A2 (es) Anticuerpos anti-glucagón
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP12011879A (es) Anticuerpo anti-tslp modificado por técnicas de ingeniería genética
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
AR078346A1 (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
BR112015023557A2 (pt) proteínas de ligações dual específicas direcionadas contra tnfa
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
UY33202A (es) Proteínas de unión a cd127
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
BR112013023513A2 (pt) anticorpos que ligam tgf-alfa e epiregulina
ECSP13012523A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33631A (es) Anticuerpos anti-cd48 y usos de los mismos
AR115423A2 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
AR129996A2 (es) Anticuerpos dirigidos contra il-33 y sus usos
AR095235A1 (es) Anticuerpos dirigidos contra il-33 y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure